Sichuan Medical Products Administration, Chengdu, 610017, China.
State Key Laboratory of Characteristic Chinese Drug Resources in Southwest China, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
J Ethnopharmacol. 2025 Jan 30;337(Pt 1):118782. doi: 10.1016/j.jep.2024.118782. Epub 2024 Sep 3.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by non-specific inflammation. Managing UC presents significant challenges due to its chronic nature and high recurrence rates. Indigo naturalis has emerged as a potential therapeutic agent in clinical UC treatment, demonstrating advantages in alleviating refractory UC and maintaining remission periods compared to other therapeutic approaches.
This review aims to elucidate the potential mechanisms underlying the therapeutic effects of indigo naturalis in UC treatment, assess its clinical efficacy, advantages, and limitations, and provide insights into methods and strategies for utilizing indigo naturalis in UC management.
Comprehensive data on indigo naturalis were collected from reputable online databases including PubMed, GreenMedical, Web of Science, Google Scholar, China National Knowledge Infrastructure Database, and National Intellectual Property Administration.
Clinical studies have demonstrated that indigo naturalis, either alone or in combination with other drugs, yields favorable outcomes in UC treatment. Its mechanisms of action involve modulation of the AHR receptor, anti-inflammatory properties, regulation of intestinal flora, restoration of the intestinal barrier, and modulation of immunity. Despite its efficacy in managing refractory UC and prolonging remission periods, indigo naturalis treatment is associated with adverse reactions, quality variations, and inadequate pharmacokinetic investigations.
The therapeutic effects of indigo naturalis in UC treatment are closely linked to its ability to regulate the AHR receptor, exert anti-inflammatory effects, mcodulate intestinal flora, restore the intestinal barrier, and regulate immunity. Addressing the current shortcomings, including adverse reactions, quality control issues, and insufficient pharmacokinetic data, is crucial for optimizing the clinical utility of indigo naturalis in UC management. By refining patient-centered treatment strategies, indigo naturalis holds promise for broader application in UC treatment, thereby alleviating the suffering of UC patients.
溃疡性结肠炎（UC）是一种慢性炎症性肠病，其特征为非特异性炎症。由于其慢性性质和高复发率，UC 的管理存在重大挑战。靛蓝天然物已成为临床 UC 治疗中的一种潜在治疗剂，与其他治疗方法相比，在缓解难治性 UC 和维持缓解期方面具有优势。
本综述旨在阐明靛蓝天然物治疗 UC 的潜在机制，评估其临床疗效、优势和局限性，并为利用靛蓝天然物治疗 UC 提供方法和策略。
从 PubMed、GreenMedical、Web of Science、Google Scholar、中国国家知识基础设施数据库和国家知识产权局等知名在线数据库中全面收集有关靛蓝天然物的资料。
临床研究表明，靛蓝天然物单独或与其他药物联合使用，在 UC 治疗中取得了良好的效果。其作用机制涉及 AHR 受体调节、抗炎作用、肠道菌群调节、肠道屏障恢复和免疫调节。尽管在治疗难治性 UC 和延长缓解期方面有效，但靛蓝天然物治疗与不良反应、质量变化和不足的药代动力学研究有关。
靛蓝天然物治疗 UC 的疗效与其调节 AHR 受体、发挥抗炎作用、调节肠道菌群、恢复肠道屏障和调节免疫的能力密切相关。解决当前的缺点，包括不良反应、质量控制问题和不足的药代动力学数据，对于优化靛蓝天然物在 UC 管理中的临床应用至关重要。通过制定以患者为中心的治疗策略，靛蓝天然物有望更广泛地应用于 UC 治疗，从而减轻 UC 患者的痛苦。
